ANI Pharmaceuticals | ANIP - 流动负债



金融业
股票价格
USD
资产
USD 1.44B
现金及等价物
USD 285.59M
销售成本
USD 122.88M
流动资产
USD 753.12M
流动负债
USD 278.11M
债务
USD 617.04M
EBIT
USD 29.13M
EBITDA
USD 65.36M
员工
642
EPS每股收益
USD 2.33
股本和储备
USD 540.72M
销售毛利
USD 124.18M
债务利息支出
USD 4.41M
贷款资金
USD 291.84M
市值
USD 1.56B
净收入
USD 32.35M
营业费用
USD 217.93M
营业利润
USD 29.13M
普通股股本
USD 22.49M
PE价格收益
37.99
税前利润
USD 49.52M
销售收入
USD 247.06M
销售和管理费用
USD 82.79M
股票
USD 143.07M
贸易债权人
USD 62.58M
应收帐款人
USD 281.08M


流动负债 更改 日
AbbVie USD 43.29B 3.9B 2025-12
ANI Pharmaceuticals USD 278.11M 7.56M 2025-12
Assertio Holdings USD 166.78M 34.25M 2025-09
Aurora Cannabis CAD 145.94M 21.82M 2025-12
Canopy Growth CAD 98.29M 17.19M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Emergent BioSolutions USD 651.3M 12.7M 2023-12
Heron Therapeutics USD 96.1M 6.39M 2025-12
Hikma Pharmaceutical USD 1.45B 603M 2025-12
Knight Therapeutics CAD 165.26M 12.58M 2025-12
Nektar Therapeutics USD 66.34M 5.05M 2025-09
Novartis USD 27.28B 4.72B 2025-12
Omeros USD 85.5M 2.28M 2025-06
Perrigo USD 1.01B 132.4M 2025-12
Sun Pharmaceuticals INR 234.15B 52.21B 2025-09
Teva Pharmaceutical Industries USD 13.46B 1.96B 2025-12